En vivo
FierceBiotechAvalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugsThermo FisherThermo Fisher Scientific Q1 Earnings Call Highlights - Yahoo FinanceAgilentDoes Agilent (A) Settling Axion Dispute Clarify Its Push Into Cloud Lab Data Recurring Revenues? - simplywall.st10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - Yahoo Finance10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpaceThermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking AlphaMOONS'How Artemis will help the U.S. create a moon base - NBC NewsAgilentAgilent Technologies Inc (A) Shares Fall 5.0% -- What GF Score o - GuruFocusThermo FisherThermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatchFierceBiotechDespite data concerns, Roche’s oral SERD can still be largest product in company history: execFierceBiotechRegeneron ushers in new genetic medicine era with groundbreaking gene therapy approvalThermo FisherThermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business Journals
FierceBiotech 24 abr 2026

Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs

Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs

Original
Contenido no disponible. Consulta la fuente original.